Recursion Pharmaceuticals Summit Therapeutics: 2026 Insight
Two biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
A straightforward overview of how to pick affordable index funds, focusing on cost, track record, and alignment with your goals.
23,644 articlesTwo biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
A man inherits his mother’s home and avoids a six-figure capital gains tax thanks to the stepped-up basis. The rule r...
A Chinese AI model is reported to rival US leaders in performance, sparking a reassessment of investments in data cen...
After a dramatic fall, Canopy Growth has staged a cautious comeback. This article breaks down whether canopy growth s...
The 2026 IPO boom is broadening beyond AI megadeals as mid-cap and overlooked sectors attract new capital. A busy sec...
Apple pushes to a fresh all-time high as AI-enabled products and a robust services ecosystem drive growth. The move w...
SpaceX is attracting renewed investor interest as revenue streams expand beyond launches. With Starlink, NASA deals, ...
Blue Owl Capital holds a sizable stake in Freedom Fuel, the Northeast gas chain known for its $3.47 per gallon pricin...
RPM International just posted a record Q4 EBIT across its segments. Alongside an insider Form 4 filing, this raises q...
CubeSmart sits in a crowded self-storage field. This guide breaks down the key indicators I watch to assess whether C...
Fuel prices could swing dramatically as geopolitical tensions in the Middle East escalate. Analysts warn the pump cou...
This analysis unpacks Interface (Tile)'s Q4 2025 earnings, translating numbers into a practical view for investors. L...